Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Genfit    GNFT   FR0004163111

GENFIT

(GNFT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
02/17/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
16.67(c) 16.33(c) 16.37(c) 16.47(c) 15.84 Last
151 348 234 212 131 918 163 105 638 370 Volume
-0.77% -2.04% +0.24% +0.61% -3.83% Change
More quotes
Financials (EUR)
Sales 2019 17,3 M
EBIT 2019 -86,9 M
Net income 2019 -95,2 M
Finance 2019 106 M
Yield 2019 -
Sales 2020 22,4 M
EBIT 2020 -116 M
Net income 2020 -123 M
Finance 2020 260 M
Yield 2020 -
P/E ratio 2019 -5,40x
P/E ratio 2020 -5,25x
EV / Sales2019 30,9x
EV / Sales2020 16,9x
Capitalization 639 M
More Financials
Company
Genfit is a leading European biopharmaceutical group. It specializes in the discovery and development of drugs for preventing and treating risk factors related to cardiometabolic pathologies (atherosclerosis, dyslipidemias, hypertension, diabetes, obesity, etc.) and inflammatory diseases. Genfit's... 
More about the company
Surperformance© ratings of Genfit
Trading Rating : Investor Rating :
More Ratings
Latest news on GENFIT
02/20CORRECTION - GENFIT : Unblinding of Phase 3 RESOLVE-IT Data Deferred
GL
02/20GENFIT : Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exch..
PU
02/20GENFIT : Unblinding of Phase 3 RESOLVE-IT Data Deferred
GL
01/23GENFIT : Answers Investors' Questions Raised Today - January 23, 2020
PU
01/22GENFIT : 2020 Financial Calendar
AQ
01/21GENFIT : 2020 Financial Calendar
GL
01/13GENFIT : 2019 Half-Year Report of Liquidity Contract with Credit Industriel et C..
AQ
01/10GENFIT : 2019 Half-Year Report of Liquidity Contract with Crédit Industriel et C..
GL
2019GENFIT : Monthly statement on outstanding equity shares and voting rights
CO
2019GENFIT : Outcome of the Ordinary and Extraordinary Shareholders Meeting of Novem..
AQ
2019GENFIT : Outcome of the Ordinary and Extraordinary Shareholders' Meeting of Nove..
GL
2019GENFIT : Positive 42-month DSMB Recommendation for Continuation of Phase 3 RESOL..
AQ
2019GENFIT : Positive 42-month DSMB Recommendation for Continuation of Phase 3 RESOL..
AQ
2019GENFIT Announces Results of NIS4, an Investigational Non-Invasive NASH Diagno..
GL
2019GENFIT : Reports Third Quarter 2019 Financial Information
AQ
More news
News in other languages on GENFIT
11:00aGENFIT : en repli après le décalage de résultats importants
10:58aGENFIT : Portzamparc abaisse son objectif de cours
10:42aGENFIT : Bryan Garnier reste à l'Achat
10:31aGENFIT : Kepler Cheuvreux reste à l'Achat
06:02aGENFIT : parmi les plus fortes baisses du SRD à la mi-séance du vendredi 21 févr..
More news
Analyst Recommendations on GENFIT
More recommendations
Sector news : Biotechnology & Medical Research - NEC
02/20Anglo American Discloses All Mine Deaths in Industry Shift--Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift -- Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift
DJ
02/20GlaxoSmithKline Invests $50 Million in Biotech Startup's Cell-Therapy Program
DJ
02/19Five Prime Therapeutics In License Agreement with Seattle Genetics
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart GENFIT
Duration : Period :
Genfit Technical Analysis Chart | GNFT | FR0004163111 | MarketScreener
Technical analysis trends GENFIT
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 64,26  €
Last Close Price 16,47  €
Spread / Highest target 538%
Spread / Average Target 290%
Spread / Lowest Target 9,29%
EPS Revisions
Managers
NameTitle
Pascal Prigent CEO & EVP-Marketing & Development
Jean-François Mouney Chairman
Dean W. Hum Chief Operating Officer
Nathalie Huitorel EVP, Chief Financial & Administrative Officer
Carol L. Addy Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
GENFIT-6.69%690
LONZA GROUP19.03%31 732
IQVIA HOLDINGS INC.6.23%31 649
SEATTLE GENETICS, INC.3.56%20 383
CELLTRION, INC.--.--%19 812
INCYTE CORPORATION-5.61%17 943